In the Chinese pharmaceutical market, Budesonide mainly has three dosage forms, including inhalation suspension, gas (powder) aerosol, and nasal spray. The most common one is Budesonide inhalation suspension, which was first developed and produced by AstraZeneca. In 2001, Budesonide entered the Chinese market. By 2020, the main manufacturers of Budesonide in China are AstraZeneca, Chia Tai Tianqing, Synmosa Biopharma, and Lunan.
According to the analyst's market research, the sales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%. However, the sales of Budesonide decreased by 29.30% in 2020 because of the COVID-19 epidemic. The sales revenue in 2020 was approximately CNY1.1 billion. With the improvement of the epidemic situation, the analyst predicts that the sales of Budesonide in China will have a recovery growth in the short run.
In recent years, the respiratory sector in the Chinese pharmaceutical market has a growth trend, mainly due to the heavy burden of asthma patients, the high smoking rate, and the deepening of aging. Thus, the analyst analyzes that in addition to the recovery growth, the sales of Budesonide will increase in 2021-2025 as the market expands.
Topics Covered:
- The impact of COVID-19 on China's budesonide market
- Sales value and volume of China's budesonide 2016-2020
- Competitive landscape of China's budesonide market
- Prices of budesonide in China
- Prices of budesonide in China by regions and manufacturers
- Analysis of factors affecting the development of China's budesonide market
- Prospect of China's budesonide market from 2021 to 2025
What is the estimated value of the Chinese Budesonide Market?
What is the growth rate of the Chinese Budesonide Market?
What is the forecasted size of the Chinese Budesonide Market?
Who are the key companies in the Chinese Budesonide Market?
Report Attribute | Details |
---|---|
No. of Pages | 50 |
Published | April 2021 |
Forecast Period | 2016 - 2025 |
Estimated Market Value ( CNY | CNY 1074 Million |
Forecasted Market Value ( CNY | CNY 1742 Million |
Compound Annual Growth Rate | 5.5% |
Regions Covered | China |
No. of Companies Mentioned | 5 |
Table of Contents
Samples
LOADING...
Companies Mentioned
- AstraZeneca Pty Ltd
- AstraZeneca AB
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Synmosa Biopharma Corporation
- Lunan Pharmaceutical Group Corporation
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...